Author: Moore, David ; Owen, Meriem Bensalem ; Krauss, Gregory L. ; Kalra, Arun ; Knowlton, Robert ; Herrman, Craig ; Morales, Sarug Reyes ; Lasso, Jorge ; Barroso, Noe ; Davis, Ronald ; Charlet, Michael ; Clement, Jean-Francois ; Cristalli, Diana ; Nieto, Flavia ; Thomson, Alfredo ; Goodpasture, Hewitt ; Ali, Imran ; Consalvo, Damián E. ; Jain, Sanjay ; Rodríguez, Ildefonso ; Biton, Victor ; Armstrong, Robert ; Shneker, Bassel ; Mitchell, Wendy ; Hwang, Paul ; Klein, Pavel ; Nofal, Pedro ; Flamini, J. ; Bautista, Ramon ; Enlow, Thomas ; Campanille, Verónica ; Kankirawatana, Pongkiat ; Ayala, Ricardo ; Renfroe, Ben ; Miller, John ; Zuin, Daniel ; Silva, Walter ; French, Jacqueline A. ; Lesch, David ; Krauss, Gregory ; Hogan, Robert ; Rogawski, Michael A. ; Squillacote, David ; Floridia, Jorge ; Halford, Jonathan ; Steiner, David ; Firstenfeld, Alfredo ; Modur, Pradeep ; Teasley, Jean ; Hernandez, Marcelo Leiva ; McLachlan, Richard ; Yang, Haichen ; Ferreira, Jose ; Yerby, Mark ; Webb, Randall ; Sosa, Veronica ; Aung-Din, Ronald ; Sperling, Michael ; Klapper, Jack ; Chung, Steve ; Elterman, Roy ; Brown, Lawrence ; Kumar, Dinesh ; Ilari, Rita ; Wheless, James ; Wilfong, Angus ; Pillay, Neelan ; Sfaello, Ignacio ; Pociecha, Juan ; Puri, Vinay ; Mesri, Jacobo ; Milian, Albino Contreras ; Miranda, Fernando ; Fessler, Albert ; Gruenthal, Michael ; Leroy, Robert ; Conry, Joan ; Szaflarski, Jerzy ; Laurenza, Antonio ; Tenhamm, Eugenio ; Brower, Richard ; Peralta, Balduin Lawson ; King-Stephens, David

OBJECTIVETo assess efficacy and safety of once-daily 8 or 12 mg perampanel, a noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor antagonist, when added to concomitant antiepileptic drugs (AEDs) in the treatment of drug-resistant partial-onset seizures.METHODSThis was a multicenter, double-blind, placebo-controlled trial (ClinicalTrials.gov identifier: NCT00699972). Patients (≥12 years, with ongoing seizures despite 1-3 AEDs) were randomized (1:1:1) to once-daily perampanel 8 mg, 12 mg, or placebo. Following baseline (6 weeks), patients entered a 19-week double-blind phase: 6-week titration (2 mg/week increments to target dose) followed by a 13-week maintenance period. Percent change in seizure frequency was the primary endpoint; 50% responder rate was the primary endpoint for EU registration.RESULTSOf 388 patients randomized and treated, 387 provided seizure frequency data. Using this intent-to-treat population over the double-blind phase, the median percent change in seizure frequency was -21.0%, -26.3%, and -34.5% for placebo and perampanel 8 and 12 mg, respectively (p = 0.0261 and p = 0.0158 for 8 and 12 mg vs placebo, respectively). Fifty percent responder rates during the maintenance period were 26.4%, 37.6%, and 36.1%, respectively, for placebo, perampanel 8 mg, and perampanel 12 mg; these differences were not statistically significant for 8 mg (p = 0.0760) or 12 mg (p = 0.0914). Sixty-eight (17.5%) patients discontinued, including 40 (10.3%) for adverse events. Most frequent treatment-emergent adverse events were dizziness, somnolence, irritability, headache, fall, and ataxia.CONCLUSIONSThis trial demonstrated that once-daily, adjunctive perampanel at doses of 8 or 12 mg improved seizure control in patients with uncontrolled partial-onset seizures. Doses of perampanel 8 and 12 mg were safe, and tolerability was acceptable.CLASSIFICATION OF EVIDENCEThis study provides Class I evidence that once-daily 8 and 12 mg doses of adjunctive perampanel are effective in patients with uncontrolled partial-onset seizures.

01 Mar 1959·Applied Microbiology

A New Technique for the Use of Sodium Azide (Hydrazoic Acid) as an Inhibitive Agent

Article

Author: Gerencser, V. F. ; Weaver, R. H.

NaN₃ in an acid medium was found to be volatile (as hydrazoic acid).Agar media were streaked with organisms and placed in a closed jar containing an open beaker containing NaN₃ solution in HCl.Gram-neg. bacterial growth on the agar plates was inhibited while gram-pos. bacterial growth was not affected.

Large Pilot CAER Heat Integrated Post-combustion CO<sub>2</sub> Capture Technology for Reducing the Cost of Electricity

Author: Richburg, Lisa ; Liu, Kunlei ; Nikolic, Heather ; Placido, Andrew ; Thompson, Jesse

News (Medical) associated with University of Kentucky Research Foundation

13 Aug 2024

·www.businesswire.com

XLerator Network Selects 8 Life Science Startups Across Southeast for NIH-Funded Entrepreneurship Program: I-RED's Second Cohort Announced

LOUISVILLE, Ky.--( BUSINESS WIRE )--XLerateHealth (XLH), a nationally recognized healthcare accelerator headquartered in Louisville, KY, in partnership with the University of Kentucky (UK) through UK Innovate, announced the selection of eight innovators across the Southeast IDeA State region (the XLerator Network), to participate in the National Institutes of Health (NIH) funded IDeA Regional Entrepreneurship Development (I-RED) Program. Participants were selected through a competitive application process for work on technologies that include Medical Devices and Therapeutics. Daniel Bonthius, MD/PhD , Co-founder of Apex Orthopaedic, LLC (Clemson University, SC) is developing a novel surgical system called R-FIX that utilizes rib fixation to correct early onset spinal deformities. Rani Brooks, PhD , Founder of BioPhoundry, LLC (Tulane University, LA) has developed a synthetic biology platform that accelerates drug-discovery for precision antibiotics to combat drug-resistant infections. Brittany Levy, MD , Founder of TalkiTourni, LLC (University of Kentucky, KY), created an automated emergency tourniquet device aimed to improve rates of adequately applied tourniquets outside of the hospital setting. Michelle Martinez, PhD , Founder of Dynamiko Pharmaceutics, LLC (Universidad Central del Caribe, Puerto Rico) is developing affordable and selective anticancer compounds that target a predominant pathway in Triple Negative Breast Cancer. Brad Profitt, DC, DPT, DScPT , Founder of Ortho-HAB, LLC (Marshall University, WV) has developed a medical device, KneeXT, geared towards recovering knee extension post trauma/injury/surgery. Mark Tseytlin, PhD , Co-founder of BioMap5D, LLC (West Virginia University, WV) is developing molecular imaging medical devices that hold promise for diagnosing/treating cancer, as well as detecting and treating implant infections. M’Hamed Turki, MD , a gastroenterology and endoscopic fellow (Marshall University, WV) has invented an oropharyngeal cannula that is attached to a bite guard, and allows the passage of endoscopes and helps prevent hypoxia during upper endoscopies. Ken Webb, PhD , Co-founder of NeuroHope Therapeutics, Inc (Clemson University, SC) is developing a drug-loaded, polymer-based nanotherapeutic to treat central nervous system trauma. Their first indication will be acute spinal cord injury. “ Our team is grateful to the NIH for their continuous support of academic technology commercialization. The resources made available to researchers and clinicians in the IDeA States by this grant are invaluable. The XLerator Network’s External Advisory Committee is excited about the eight innovators selected to participate in the second I-RED cohort, and is delighted to have been part of the selection process,” said Dr. David McLoughlin, Chair, External Advisory Committee, XLerator Network (XLN). The goal of the I-RED program is to help selected participants acquire the fundamental business and entrepreneurial skills needed to successfully commercialize their technologies. As part of this program, XLN will expand the suite of healthcare focused commercialization modules on the ScholarRx platform. The team will also provide wrap-around commercialization services that include healthcare focused programming, talent access through their Executive-On-Roster® (XOR®) platform, and test a newly created Mentor / Startup Founder “Customer Discovery” matching program. “ This second NIH/NIGMS STTR award will allow us to build on prior work to develop, launch, test, and validate entrepreneurship education and training tools that foster the translation of promising biomedical discoveries and technologies from research laboratories into commercial products,” noted Jackie Willmot, CEO and Co-founder of XLerateHealth. About XLerateHealth XLerateHealth’s mission is to cultivate and grow impactful healthcare innovation in the Midwest, Southeast, and other areas of the country where great innovation often goes unrecognized and underfunded. Founded in 2012, XLH supports the development of healthcare innovation through its healthcare accelerator, which helps startup founders commercialize their business and attract funding. XLerateHealth also leads the efforts to build and operate the XLerator Network, an NIH-funded partnership with Academic Lead University of Kentucky along with 24 other academic institutions in the Southeast. The objective of this work is to increase the commercialization of promising life science and healthcare innovations in the NIH-designated Southeast Institutional Development Award (IDeA) states. About UK Innovate UK Innovate at the University of Kentucky is the innovation, entrepreneurship and economic enterprise for University of Kentucky Research. Through technology commercialization, corporate partnerships, social innovation, innovation training and economic development initiatives related to UK’s research innovations, talent and community, UK Innovate works to move ideas into the world faster, where they can make the greatest social and economic impact possible.

12 Oct 2023

·www.prnewswire.com

Pulmonary Fibrosis Foundation Expands Care Center Network for PF Patients

Seven Sites Join Network as Clinical Associate Members CHICAGO, Oct. 12, 2023 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) announced that seven medical centers have joined the PFF Care Center Network (CCN) as Clinical Associate members, a new membership option. Each of these Clinical Associates will collaborate with an existing Care Center Network site to help bring the resources of the PFF to even more people living with pulmonary fibrosis (PF) and interstitial lung disease (ILD). The Care Center Network includes 81 CCN sites and seven Clinical Associates in 39 states. Continue Reading (PRNewsfoto/The Pulmonary Fibrosis Foundation) "With the addition of seven Clinical Associate members, we are actively addressing the critical need to expand access for patients with PF and ILD to the resources available from the PFF as well as connecting more patients with providers committed to advancing the diagnosis and treatment of PF," said Dr. Sonye Danoff, PFF Senior Medical Advisor, PFF Care Center Network. "Our Clinical Associates will extend care to additional people living with these serious conditions and, in collaboration with CCN sites, they will provide patient education, clinical care and research opportunities including clinical trials." The newly designated Clinical Associate members of the PFF Care Center Network are: Avera Medical Group Pulmonary & Sleep Medicine (Sioux Falls, SD): Dr. Fady Jamous, Center Director Chest Medicine Associates Center for Interstitial Lung Disease (South Portland, ME): Dr. Meagan Moore, Center Director ChristianaCare (Newark, DE): Dr. Renee Dixon, Center Director Ochsner LSU Health Shreveport – Academic Medical Center(Shreveport, LA): Dr. Prangthip Charoenpong, Center Director StatCare Pulmonary (Knoxville, TN): Dr. Eric Weaver, Center Director St. Luke's University Health Network (Fountain Hill, PA): Dr. Douglas Corwin, Center Director University of New Mexico (Albuquerque, NM): Dr. Nour Ass'ad, Center Director Through the CCN, Care Centers and Clinical Associates collaborate to promote and provide quality care to those living with PF. Each Clinical Associate is paired with a current Care Center member so they may collaborate to expand and improve pulmonary fibrosis care. While Care Centers offer complete multi-disciplinary care on site, Clinical Associates may refer patients for procedures or services they are unable to offer. Clinical Associates actively participate in the CCN in working groups and committees, including the Nurse and Allied Health Network, which provides professional development and networking opportunities. More than 250,000 Americans are living with PF and ILD and over 50,000 new cases are diagnosed annually. There are over 200 types of ILD, which are characterized by varied amounts of inflammation, scarring, or both. This damages the ability of the lungs to absorb oxygen from the air. PF means scarring of the lung and can be seen in many types of ILD. The 88 sites now operating in the PFF Care Center Network are: Alabama University of Alabama at Birmingham (Birmingham) Arizona St. Joseph's Hospital (Phoenix) Banner University Medical Center (Phoenix ) University of Arizona (Tucson) California Cedars-Sinai Medical Center (Los Angeles) Center for Advanced Lung Disease at Keck Medicine of USC (Los Angeles) Loma Linda University Medical Center (Loma Linda) Stanford Health Center (Palo Alto) University of California at Davis Interstitial Lung Disease Program (Sacramento) University of California at Los Angeles (Los Angeles) University of California at San Diego (San, Diego) University of California at San Francisco (San Francisco) Colorado National Jewish Health (Denver) University of Colorado Anschutz Medical Campus (Aurora) Connecticut Yale School of Medicine (New Haven) Delaware **ChristianaCare Pulmonary Associates (Newark) NEW Florida Cleveland Clinic Florida (Weston) University of Florida (Gainesville) University of Miami (Miami) University of South Florida – Tampa General Hospital (Tampa) Georgia Emory University Hospital (Atlanta) Piedmont Healthcare (Atlanta) Illinois Loyola University Medical Center (Maywood) Northwestern Memorial Hospital (Chicago) Rush University Medical Center (Chicago) University of Chicago (Chicago) Indiana Indiana University (Bloomington) Iowa University of Iowa (Iowa City) Kansas The University of Kansas Hospital (Kansas City) Kentucky University of Kentucky Research Foundation (Lexington) University of Louisville School of Medicine (Louisville) Louisiana **Ochsner LSU Health Shreveport – Academic Medical Center (Shreveport) NEW Tulane University School of Medicine (New Orleans) Maine **Chest Medicine Associates Center for Interstitial Lung Disease (South Portland) NEW Maryland Johns Hopkins University (Baltimore) University of Maryland Medical Center (Baltimore) Massachusetts Beth Israel Deaconess Medical Center (Boston) Massachusetts General Hospital (Boston) St. Elizabeth's Medical Center (Boston) Michigan Corewell Health East (Royal Oak) Henry Ford Health System (Detroit) Spectrum Heath System (Grand Rapids) University of Michigan Health System (Ann Arbor) Minnesota University of Minnesota Medical Center (Minneapolis) Mayo Clinic (Rochester) Missouri St. Luke's Hospital (Chesterfield) Washington University School of Medicine (St. Louis) Nebraska Creighton University (Omaha) University of Nebraska Medical Center (Omaha) New Hampshire Dartmouth Health (Hanover, NH) New Mexico **University of New Mexico (Albuquerque) NEW New York Columbia University Medical Center (New York) New York University School of Medicine (New York) Stony Brook University Hospital (Stony Brook) University of Rochester Medical Center (Rochester) Weill-Cornell Medical Center (New York) North Carolina Duke University Medical Center (Durham) LeBauer Health Care at Cone Health (Greensboro) University of North Carolina Chapel Hill (Chapel Hill) Ohio Cleveland Clinic (Cleveland) The Ohio State University Wexner Medical Center (Columbus) University of Cincinnati Medical Center (Cincinnati) Oklahoma OU Health (Oklahoma City) Oregon The Oregon Clinic (Portland) Pennsylvania Penn State Milton S. Hershey Medical Center (Hershey) **St. Luke's University Health Network (Fountain Hill) NEW Temple Health (Philadelphia) Thomas Jefferson University Hospital (Philadelphia) University of Pennsylvania (Philadelphia) University of Pittsburgh (Pittsburgh) Rhode Island Rhode Island Hospital (Providence) South Carolina Medical University of South Carolina, (Charleston) South Dakota **Avera Medical Group Pulmonary & Sleep Medicine (Sioux Falls) NEW Tennessee **StatCare Pulmonary (Knoxville) NEW Vanderbilt University Medical Center (Nashville) Texas Baylor University Medical Center (Dallas) Houston Methodist Hospital (Houston) University of Texas Southwestern Medical Center (Dallas) University of Texas Health Science Center (Houston) The University of Texas Health Science Center (San Antonio) Utah University of Utah Health Care (Salt Lake City) Vermont The University of Vermont Medical Center (Burlington) Virginia Inova Fairfax Medical Campus (Falls Church) University of Virginia Health Systems (Charlottesville) VCU Health (Richmond) Washington University of Washington Medical Center (Seattle) Wisconsin Froedtert & the Medical College of Wisconsin Froedtert Hospital (Milwaukee) University of Wisconsin (Madison) **Clinical Associates About the Pulmonary Fibrosis Foundation The mission of the Pulmonary Fibrosis Foundation is to accelerate the development of new treatments and ultimately a cure for pulmonary fibrosis. Until this goal is achieved, the PFF is committed to advancing improved care of patients with PF and providing unequaled support and education resources for patients, caregivers, family members, and health care providers. The PFF has a four-star rating from Charity Navigator and is an accredited charity by the Better Business Bureau (BBB) Wise Giving Alliance. The Foundation has met all of the requirements of the National Health Council Standards of Excellence Certification Program® and has earned the Guidestar Platinum Seal of Transparency. For more information, visit pulmonaryfibrosis.org or call 844.TalkPFF (844.825.5733). Contact: Dorothy Coyle, 773-332-6201 SOURCE The Pulmonary Fibrosis Foundation

07 Dec 2022

·www.prnewswire.com

7 Medical Centers Join Pulmonary Fibrosis Foundation's Care Center Network

Hospitals nationwide specialize in treating and supporting people living with lung disease CHICAGO, Dec. 7, 2022 /PRNewswire/ -- More than 250,000 Americans living with pulmonary fibrosis now have access to expert treatment at seven medical centers that have been added to the Pulmonary Fibrosis Foundation's (PFF) Care Center Network (CCN). With the new sites, the PFF Care Center Network totals 81 medical facilities in 35 states across the U.S. Continue Reading The Pulmonary Fibrosis Foundation's Care Center Network now features 81 medical centers in 35 states that offer specialized care and support for individuals living with pulmonary fibrosis. "We are pleased to broaden our reach to help more patients access specialized care," said Jessica Shore, PhD, RN, Vice President, Clinical Affairs and Quality for the PFF. "We couldn't expand for two years due to the COVID-19 pandemic. This year we resumed our expansion plans and added a total of 13 leading pulmonology centers to our network." View the Pulmonary Fibrosis Foundation's website to find a Care Center location near you. New PFF Care Center Sites The newest medical centers to receive the Care Center Network designation are: Cedars-Sinai (Los Angeles, Calif.) Coordinator: Linda Yann, RN Corewell Health East (Royal Oak, Mich.) Coordinator: Heather Whitt, RN Dartmouth Hitchcock Medical Center (Lebanon, N.H.) Coordinator: Heidi Pelchat, RT Loma Linda University (Loma Linda, Calif.) Coordinator: Jeanette Merrill-Henry University of California San Diego (San Diego, Calif.) Coordinator: Nadine Basbas University of Nebraska Medical Center (Omaha, Neb.) Coordinator: Jill Naiberk The University of North Carolina at Chapel Hill (Chapel Hill, N.C.) Coordinator: Liesl Jeffreys Six additional sites joined the network in August: Center for Advanced Lung Disease at Keck Medicine of University of Southern California (Los Angeles, Calif.) Coordinator: Debbie Benitez RN, MSN, ACNP-BC Froedtert & the Medical College of Wisconsin Froedtert Hospital (Milwaukee, Wis.) Coordinator: Kelsey Cramer Rush University Medical Center (Chicago, Ill.) Coordinator: Sarah Lynne, NP OU Health (Oklahoma City, Okla.) Coordinator: Suzy Yandell University of South Florida-Tampa General Hospital (Tampa, Fla.) Coordinator: Nicole Davis, RN VCU Health (Richmond, Va.) Coordinator: Shana Marannano Medical centers in the CCN have met criteria developed with both pulmonary fibrosis medical experts and patient input. All sites offer teams with expertise in pulmonary medicine, rheumatology, radiology, pathology, and dedicated clinical staff. Healthcare providers at Care Centers collaborate with the PFF to actively engage their local PF communities with resources including support groups, educational activities and materials for patients, caregivers and their loved ones. The PFF also coordinates with sites on research projects. The 81 sites now operating in the PFF Care Center Network are: Alabama University of Alabama at Birmingham (Birmingham) Arizona St. Joseph's Hospital (Phoenix) Banner University Medical Center (Phoenix ) University of Arizona (Tucson) California Cedars-Sinai (Los Angeles) NEW Center for Advanced Lung Disease at Keck Medicine of USC (Los Angeles) Loma Linda University Medical Center (Loma Linda) NEW Stanford Health Center (Palo Alto) University of California at Davis Interstitial Lung Disease Program (Sacramento) University of California at Los Angeles (Los Angeles) University of California at San Diego (San, Diego) NEW University of California at San Francisco (San Francisco) Colorado National Jewish Health (Denver) University of Colorado Anschutz Medical Campus (Aurora) Connecticut Yale School of Medicine (New Haven) Florida Cleveland Clinic Florida (Weston) University of Florida (Gainesville) University of Miami (Miami) University of South Florida – Tampa General Hospital (Tampa) Georgia Emory University Hospital (Atlanta) Piedmont Healthcare (Atlanta) Illinois Loyola University Medical Center (Maywood) Northwestern Memorial Hospital (Chicago) Rush University Medical Center (Chicago) University of Chicago (Chicago) Indiana Indiana University (Bloomington) Iowa University of Iowa (Iowa City) Kansas The University of Kansas Hospital (Kansas City) Kentucky University of Kentucky Research Foundation (Lexington) University of Louisville School of Medicine (Louisville) Louisiana Tulane University School of Medicine (New Orleans) Maryland Johns Hopkins University (Baltimore) University of Maryland Medical Center (Baltimore) Massachusetts Beth Israel Deaconess Medical Center (Boston) Massachusetts General Hospital (Boston) St. Elizabeth's Medical Center (Boston) Michigan Corewell Health East (Royal Oak) NEW Henry Ford Health System (Detroit) Spectrum Heath System (Grand Rapids) University of Michigan Health System (Ann Arbor) Minnesota University of Minnesota Medical Center (Minneapolis) Mayo Clinic (Rochester) Missouri St. Luke's Hospital (Chesterfield) Washington University School of Medicine (St. Louis) Nebraska Creighton University (Omaha) University of Nebraska Medical Center (Omaha) NEW New Hampshire Dartmouth Hitchcock Medical Center (Lebanon, NH) NEW New York Columbia University Medical Center (New York) New York University School of Medicine (New York) Stony Brook University Hospital (Stony Brook) University of Rochester Medical Center (Rochester) Weill-Cornell Medical Center (New York) North Carolina Duke University Medical Center (Durham) LeBauer Health Care at Cone Health (Greensboro) The University of North Carolina Chapel Hill (Chapel Hill) NEW Ohio Cleveland Clinic (Cleveland) The Ohio State University Wexner Medical Center (Columbus) University of Cincinnati Medical Center (Cincinnati) Oklahoma OU Health (Oklahoma City) Oregon The Oregon Clinic (Portland) Pennsylvania Penn State Milton S. Hershey Medical Center (Hershey) Temple Health (Philadelphia) Thomas Jefferson University Hospital (Philadelphia) University of Pennsylvania (Philadelphia) University of Pittsburgh (Pittsburgh) Rhode Island Rhode Island Hospital (Providence) South Carolina Medical University of South Carolina, (Charleston) Tennessee Vanderbilt University Medical Center (Nashville) Texas Baylor University Medical Center (Dallas) Houston Methodist Hospital (Houston) University of Texas Southwestern Medical Center (Dallas) University of Texas Health Science Center (Houston) The University of Texas Health Science Center (San Antonio) Utah University of Utah Health Care (Salt Lake City) Vermont The University of Vermont Medical Center (Burlington) Virginia Inova Fairfax Medical Campus (Falls Church) University of Virginia Health Systems (Charlottesville) VCU Health (Richmond) Washington University of Washington Medical Center (Seattle) Wisconsin Froedtert & the Medical College of Wisconsin Froedtert Hospital (Milwaukee) University of Wisconsin (Madison) About the Pulmonary Fibrosis Foundation The mission of the Pulmonary Fibrosis Foundation is to accelerate the development of new treatments and ultimately a cure for pulmonary fibrosis. Until this goal is achieved, the PFF is committed to advancing improved care of patients with PF and providing unequaled support and education resources for patients, caregivers, family members, and health care providers. The PFF has a three-star rating from Charity Navigator and is an accredited charity by the Better Business Bureau (BBB) Wise Giving Alliance. The Foundation has met all of the requirements of the National Health Council Standards of Excellence Certification Program® and has earned the Guidestar Platinum Seal of Transparency. For more information, visit pulmonaryfibrosis.org or call 844.TalkPFF (844.825.5733). Contact: Dorothy Coyle 773-332-6201 SOURCE The Pulmonary Fibrosis Foundation

100 Deals associated with University of Kentucky Research Foundation

100 Translational Medicine associated with University of Kentucky Research Foundation

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 26 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Current Projects

Drug(Targets)	Indications	Global Highest Phase

WO2023028518 ( ghrelin )	Emotional lability More	Discovery

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis